

# Avik Majumdar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605649/publications.pdf>

Version: 2024-02-01

64  
papers

1,255  
citations

471509

17  
h-index

377865

34  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2170  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
2	Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1276-1292.	3.7	124
3	Risk stratification in acute upper GI bleeding: comparison of the AIMS65 score with the Glasgow-Blatchford and Rockall scoring systems. <i>Gastrointestinal Endoscopy</i> , 2016, 83, 1151-1160.	1.0	112
4	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
5	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	7.3	95
6	Bacterial Infections Change Natural History of Cirrhosis Irrespective of Liver Disease Severity. <i>American Journal of Gastroenterology</i> , 2017, 112, 588-596.	0.4	82
7	Frailty in advanced liver disease. <i>Liver International</i> , 2018, 38, 2117-2128.	3.9	73
8	Management of people with early- or very early-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011650.	2.8	59
9	Referral pathways for patients with NAFLD based on non-invasive fibrosis tests: Diagnostic accuracy and cost analysis. <i>Liver International</i> , 2019, 39, 2052-2060.	3.9	49
10	Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. <i>Liver International</i> , 2017, 37, 1334-1344.	3.9	33
11	Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study. <i>Hepatology</i> , 2020, 71, 627-642.	7.3	32
12	Declining mortality in critically ill patients with cirrhosis in Australia and New Zealand between 2000 and 2015. <i>Journal of Hepatology</i> , 2017, 67, 1185-1193.	3.7	31
13	Biomarkers of bacterial translocation in advanced chronic liver disease: the key to individualizing prognosis. <i>Annals of Gastroenterology</i> , 2016, 29, 1-2.	0.6	31
14	Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. <i>World Journal of Hepatology</i> , 2020, 12, 1168-1181.	2.0	27
15	Differential Impact of Extended Criteria Donors After Brain Death or Circulatory Death in Adult Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1603-1617.	2.4	21
16	An autosomal dominant form of non-cirrhotic portal hypertension. <i>Journal of Hepatology</i> , 2015, 63, 525-527.	3.7	20
17	Changing trends of liver transplantation and mortality from non-alcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154291.	3.4	20
18	Continuous outpatient terlipressin infusion for hepatorenal syndrome as a bridge to successful liver transplantation. <i>Hepatology</i> , 2014, 60, 2125-2126.	7.3	19

#	ARTICLE	IF	CITATIONS
19	Exercise Intolerance, Benefits, and Prescription for People Living With a Fontan Circulation: The Fontan Fitness Intervention Trial (F-FIT)â€”Rationale and Design. <i>Frontiers in Pediatrics</i> , 2021, 9, 799125.	1.9	19
20	Drugâ€”induced liver injury in Australia, 2009â€”2020: the increasing proportion of nonâ€”paracetamol cases linked with herbal and dietary supplements. <i>Medical Journal of Australia</i> , 2021, 215, 261-268.	1.7	18
21	Management of people with intermediate-stage hepatocellular carcinoma. <i>The Cochrane Library</i> , 2017, 3, CD011649.	2.8	16
22	Non-alcoholic fatty liver disease: Current therapeutic options. <i>Current Opinion in Pharmacology</i> , 2021, 61, 98-105.	3.5	15
23	Australian consensus recommendations for the management of hepatitis B. <i>Medical Journal of Australia</i> , 2022, 216, 478-486.	1.7	15
24	Treatment of Hepatitis C in Patients with Cirrhosis: Remaining Challenges for Direct-Acting Antiviral Therapy. <i>Drugs</i> , 2015, 75, 823-834.	10.9	14
25	Declining Mortality of Cirrhotic Variceal Bleeding Requiring Admission to Intensive Care. <i>Critical Care Medicine</i> , 2019, 47, 1317-1323.	0.9	10
26	Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients. <i>World Journal of Gastroenterology</i> , 2017, 23, 8526-8532.	3.3	8
27	Is it safe to expand the indications for split liver transplantation in adults? A singleâ€”centre analysis of 155 inâ€”situ splits. <i>Clinical Transplantation</i> , 2022, , e14673.	1.6	5
28	The holy grail of a biomarker for â€œliver functionâ€”. <i>Clinical Liver Disease</i> , 2016, 7, 135-138.	2.1	4
29	Curve Your Enthusiasm: The Decision to Use Expanded or Original Baveno VI Criteria to Exclude High-Risk Varices. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1243-1244.	4.4	4
30	Rapid reduction of high-level pre-formed donor-specific antibodies after simultaneous liver-kidney transplantation: a report of two cases. <i>BMC Nephrology</i> , 2020, 21, 47.	1.8	4
31	The role of a novel self-expanding metal stent in variceal bleeding: a multicenter Australian and New Zealand experience. <i>Endoscopy International Open</i> , 2022, 10, E238-E245.	1.8	4
32	Emerging role of endoscopic ultrasound-guided liver biopsy. <i>Gut</i> , 2020, , gutjnl-2020-322704.	12.1	3
33	BK Nephropathy as a Cause of Renal Dysfunction in an ABO-incompatible Liver Transplant Patient. <i>Transplantation</i> , 2020, 104, e83-e84.	1.0	3
34	AIMS65: A promising upper gastrointestinal bleeding risk score but further validation required. <i>World Journal of Gastroenterology</i> , 2014, 20, 14515.	3.3	3
35	Turning the Tide on Hepatitis C Virusâ€”Related Liver Transplantation: The Return on Investment in Hepatitis C Virus Treatment in Australia and New Zealand. <i>Liver Transplantation</i> , 2022, 28, 236-246.	2.4	3
36	Prevalence and outcomes of <i>Clostridioides difficile</i> infection in liver transplant recipients. <i>Transplant Infectious Disease</i> , 2021, , e13758.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Management, outcomes and survival of an Australian IgG4-related disease cohort: The MOSAIC study. Liver International, 2021, 41, 2934-2943.	3.9	2
38	Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back?. Gut, 2021, , gutjnl-2021-325994.	12.1	2
39	Binge drinking and fibrogenesis: More than just a hangover. Liver International, 2022, 42, 6-8.	3.9	2
40	Safety first, a harmful interaction between rivaroxaban and berberine. Internal Medicine Journal, 2022, 52, 887-888.	0.8	2
41	Improved survival of cirrhotic patients with infections in Australian and New Zealand <sc>ICUs</sc> between 2005 and 2017. Liver International, 2023, 43, 49-59.	3.9	2
42	155 Risk Stratification in Acute Upper Gastrointestinal Bleeding: AIMS65 Is Superior to Glasgow-Blatchford and Rockall Scoring Systems in Predicting Inpatient Mortality. Gastrointestinal Endoscopy, 2014, 79, AB112.	1.0	1
43	Out With the Old, in With the New. Critical Care Medicine, 2018, 46, e1017.	0.9	1
44	PTU-041...Thromboelastography demonstrates a hypercoagulable profile in cirrhosis and correlates with liver disease severity. , 2019, , .		1
45	Impact of Having a Planned Additional Operation at Time of Liver Transplant on Graft and Patient Outcomes. Journal of Clinical Medicine, 2020, 9, 608.	2.4	1
46	A rare cause of ductopenia: adult onset Alagille syndrome. Pathology, 2020, 52, 610-612.	0.6	1
47	Steroid-refractory T-cell mediated rejection after human metapneumovirus infection in a liver transplant recipient. Pathology, 2021, 53, 793-794.	0.6	1
48	The clinical utility of non-invasive tests in cirrhosis: results of decision analysis modelling. Journal of Hepatology, 2017, 66, S660-S661.	3.7	0
49	THU-043-Declining mortality of cirrhotic patients requiring admission to intensive care units for serious infections: A bi-national cohort study. Journal of Hepatology, 2019, 70, e178-e179.	3.7	0
50	Are liver transplant centres critical for the critically ill patient with cirrhosis?. Journal of Hepatology, 2019, 71, 637-638.	3.7	0
51	IDDF2019-ABS-0196...Long term outcomes of utilizing donation after circulatory death grafts in liver transplantation "an australian 12-year cohort study. , 2019, , .		0
52	IDDF2019-ABS-0220...Long-term outcomes of utilizing extended criteria deceased donors in liver transplantation "an australian 12-year cohort study. , 2019, , .		0
53	Clostridium difficile infection in liver transplant recipients is uncommon and does not impact long-term survival: a case-control study. Journal of Hepatology, 2020, 73, S273.	3.7	0
54	Su1027 SX-ELLA DANIS STENT FOR THE MANAGEMENT OF REFRACTORY VARICEAL BLEEDING IN CHRONIC LIVER DISEASE: A MULTI-CENTER AUSTRALIAN AND NEW ZEALAND EXPERIENCE. Gastrointestinal Endoscopy, 2020, 91, AB271-AB272.	1.0	0

#	ARTICLE	IF	CITATIONS
55	The authors reply. Critical Care Medicine, 2020, 48, e258-e259.	0.9	0
56	Acute Confusion Following Liver Transplantation: HE or Not HE, That Is the Question. Hepatology, 2021, 73, 858-860.	7.3	0
57	The Assessment of Portal Hypertension. , 2021, , 159-171.		0
58	An essential accessory. BMJ Open Gastroenterology, 2021, 8, e000770.	2.7	0
59	Quality of life indicators in hepatic encephalopathy following supplementation with branched chain amino acids and/or synbiotics: A postâ€œhoc analysis. GastroHep, 2021, 3, 50-57.	0.6	0
60	When and How to Perform Surveillance. , 2016, , 63-72.		0
61	IDDF2020-ABS-0162â€œ...Trends in hospitalised drug-induced liver injury from 2009 to 2019 â€œ the rise of non-prescription medications. , 2020, , .		0
62	All in all, not just a clip on the wall. Digestive and Liver Disease, 2022, , .	0.9	0
63	Impact of Intensive Care Unit Discharge Delay on Liver Transplantation Outcomes. Journal of Clinical Medicine, 2022, 11, 2561.	2.4	0
64	Editorial: optimising hepatitis B vaccine response in inflammatory bowel diseaseâ€œtime to get some skin in the game. Alimentary Pharmacology and Therapeutics, 2022, 56, 353-354.	3.7	0